Topical Alpha-2 Agonist and NSAID Combination for Rosacea

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for inflammatory skin disorders like rosacea are limited in effectiveness and often associated with significant side effects, including systemic issues with α2 adrenergic receptor agonists and non-steroidal anti-inflammatory agents.

Innovation Solution

A topical combination of an α2 adrenergic receptor agonist and a non-steroidal anti-inflammatory agent, administered directly to affected skin areas, to treat or prevent inflammatory skin disorders with reduced side effects.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If oral antibiotics are used for long-term treatment, then skin eruptions are controlled, but side effects increase and patient tolerance decreases

Engineering Contradiction:

Improvecontrol of skin eruptionsVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts the active therapeutic components (α2 adrenergic receptor agonist and NSAID) from systemic administration and delivers them locally through topical application. This extraction of the essential therapeutic function from the harmful systemic delivery method resolves the contradiction by maintaining eruption control while eliminating systemic side effects.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent introduces a topical formulation as an intermediary delivery system that combines α2 adrenergic receptor agonists and NSAIDs in a localized form. This intermediary approach allows the therapeutic agents to act directly on the skin without entering systemic circulation, thereby maintaining effectiveness while reducing harmful side effects.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Object-affected harmful factors

If topical treatments are applied, then side effects are reduced, but effectiveness in treating all symptoms is limited

Engineering Contradiction:

Improveside effectsVSAvoideffectiveness

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent merges two different therapeutic mechanisms (α2 adrenergic receptor agonism for vasoconstriction and inflammation reduction, and NSAID action for prostaglandin inhibition) into a single topical formulation. This combination approach enhances the overall effectiveness of topical treatment by addressing multiple symptom pathways simultaneously while maintaining the safety advantage of localized delivery.

Inventive Principle:

Principle #5Merging (Combining)

3Reliability

If systemic medications are administered, then comprehensive treatment is achieved, but patient tolerance is limited due to side effects

Engineering Contradiction:

Improvecomprehensive treatmentVSAvoidpatient tolerance

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent extracts the therapeutic efficacy from systemic medications and relocates it to topical application. By taking out the active ingredients from oral formulation and applying them topically, the patent achieves comprehensive treatment of skin symptoms while removing the systemic side effects that limit patient tolerance.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent changes the administration route parameter from systemic (oral) to local (topical). This parameter change fundamentally alters the pharmacokinetic profile, maintaining therapeutic effectiveness at the target site while eliminating exposure to distant organs, thereby improving patient tolerance.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The combination effectively reduces symptoms of inflammatory skin disorders with minimal side effects, demonstrating improved therapeutic outcomes in animal models by significantly reducing edema and inflammation.

Implementation Method 1

Agonists of the α2 adrenoceptors have been used therapeutically for a number of conditions including hypertension, congestive heart failure, angina pectoris, spasticity, glaucoma, diarrhea, and for the suppression of opiate withdrawal symptoms

Methodology Applied

Scientific EffectVasoconstriction:

Implementation Method 2

Non-steroidal anti-inflammatory agents (NSAIDs) have been used to reduce inflammation and as analgesics

Methodology Applied

Scientific EffectEnzyme inhibition:

Data Source

PatentUS9186358B2Combination therapy for treating or preventing an inflammatory skin disorder

Publication Date: 2015.11.17 GALDERMA LAB LP

AI summary

Methods and compositions for improved treatment and prevention of an inflammatory skin disorder or a sign and/or symptom associated with the skin disorder are described. The methods involve topical application to the skin a combination of a therapeutically effective amount of an α2 adrenergic receptor agonist, such as brimonidine, and a therapeutically effective amount of a non-steroidal anti-inflammatory agent, such as diclofenac.